178 related articles for article (PubMed ID: 30507300)
1. Discovering biomarkers in bladder cancer by metabolomics.
Zhang WT; Zhang ZW; Guo YD; Wang LS; Mao SY; Zhang JF; Liu MN; Yao XD
Biomark Med; 2018 Dec; 12(12):1347-1359. PubMed ID: 30507300
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
3. Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.
Pereira F; Domingues MR; Vitorino R; Guerra IMS; Santos LL; Ferreira JA; Ferreira R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542319
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
[TBL] [Abstract][Full Text] [Related]
5. Recognition of early and late stages of bladder cancer using metabolites and machine learning.
Kouznetsova VL; Kim E; Romm EL; Zhu A; Tsigelny IF
Metabolomics; 2019 Jun; 15(7):94. PubMed ID: 31222577
[TBL] [Abstract][Full Text] [Related]
6. Discovery of urine biomarkers for bladder cancer via global metabolomics.
Shi H; Li X; Zhang Q; Yang H; Zhang X
Biomarkers; 2016 Nov; 21(7):578-88. PubMed ID: 27133288
[TBL] [Abstract][Full Text] [Related]
7. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
8. Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.
di Meo NA; Loizzo D; Pandolfo SD; Autorino R; Ferro M; Porta C; Stella A; Bizzoca C; Vincenti L; Crocetto F; Tataru OS; Rutigliano M; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456991
[TBL] [Abstract][Full Text] [Related]
9. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the metabolomic study of bladder cancer.
Amara CS; Vantaku V; Lotan Y; Putluri N
Expert Rev Proteomics; 2019 Apr; 16(4):315-324. PubMed ID: 30773067
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
Rodrigues D; Jerónimo C; Henrique R; Belo L; de Lourdes Bastos M; de Pinho PG; Carvalho M
Int J Cancer; 2016 Jul; 139(2):256-68. PubMed ID: 26804544
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
[TBL] [Abstract][Full Text] [Related]
13. Metabolomics workflow for lung cancer: Discovery of biomarkers.
Tang Y; Li Z; Lazar L; Fang Z; Tang C; Zhao J
Clin Chim Acta; 2019 Aug; 495():436-445. PubMed ID: 31103622
[TBL] [Abstract][Full Text] [Related]
14. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.
Burton C; Ma Y
Curr Med Chem; 2019; 26(1):5-28. PubMed ID: 28914192
[TBL] [Abstract][Full Text] [Related]
15. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
16. Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics.
Shao CH; Chen CL; Lin JY; Chen CJ; Fu SH; Chen YT; Chang YS; Yu JS; Tsui KH; Juo CG; Wu KP
Oncotarget; 2017 Jun; 8(24):38802-38810. PubMed ID: 28415579
[TBL] [Abstract][Full Text] [Related]
17. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
[TBL] [Abstract][Full Text] [Related]
18. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
[TBL] [Abstract][Full Text] [Related]
19. NMR-based metabolomics study of canine bladder cancer.
Zhang J; Wei S; Liu L; Nagana Gowda GA; Bonney P; Stewart J; Knapp DW; Raftery D
Biochim Biophys Acta; 2012 Nov; 1822(11):1807-14. PubMed ID: 22967815
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
